(Q36079166)

12 August 2017

1 reference

title

Antidepressant treatment of psychotic major depression: potential role of the sigma receptor (English)

1 reference

12 August 2017

1 reference

1

Stephen M Stahl

1 reference

12 August 2017

publication date

1 April 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

10

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

319-323

1 reference

Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Enhanced antidepressant effect of sigma(1) (sigma(1)) receptor agonists in beta(25-35)-amyloid peptide-treated mice

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives: novel, potent and selective sigma1 receptor ligands.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]pip eri dine.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Sigma receptors: biology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Nerve growth factor-induced neurite sprouting in PC12 cells involves sigma-1 receptors: implications for antidepressants

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Delusional depression. A distinct clinical entity?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Sertraline as monotherapy in the treatment of psychotic and nonpsychotic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

AMITRIPTYLINE IN DEPRESSIVE STATES: PHENOMENOLOGY AND PROGNOSTIC CONSIDERATIONS

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

An open label trial of C-1073 (mifepristone) for psychotic major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Is a single tricyclic antidepressant trial an active treatment for psychotic depression?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Psychotic (delusional) depression: a meta-analysis of physical treatments

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Placebo response rates in psychotic and nonpsychotic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Psychotic depression and mortality

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The Treatment of Psychotic Major Depressive Disorder with Drugs and Electroconvulsive Therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Coadministration of clozapine and fluvoxamine in psychotic patients--clinical experience

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

BMY 14802, a sigma receptor ligand for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Haloperidol competitively inhibits the binding of (+)-[3H]SKF-10,047 to sigma sites

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Rapid reversal of psychotic depression using mifepristone

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The pharmacology of the novel and selective sigma ligand, PD 144418.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Anti-amnesic effect of dimemorfan in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Venlafaxine Versus Fluvoxamine in the Treatment of Delusional Depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Effects of sigma receptor ligands on conditioned fear stress.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Treatment of unipolar depression accompanied by delusions. ECT versus tricyclic antidepressant--antipsychotic combinations

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Regulation of ionotropic glutamate receptor subunits in different rat brain areas by a preferential sigma(1) receptor ligand and potential atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Delusional unipolar depression: description and drug response

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Steroid synthesis and metabolism in the nervous system: trophic and protective effects

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

99mTc-labeled sigma-receptor-binding complex: synthesis, characterization, and specific binding to human ductal breast carcinoma (T47D) cells.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Strain differences in sigma(1) receptor-mediated behaviours are related to neurosteroid levels

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Delusional Depressions: Natural History and Response to Treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Evaluation of newer treatment interventions for psychotic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The pharmacological treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The clinical and neuroendocrine features of psychotic depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Fluvoxamine as an adjunctive agent in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The interaction between neuroactive steroids and the σ1 receptor function: behavioral consequences and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Clinical, demographic and social characteristics of psychotic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Fluvoxamine alone in the treatment of delusional depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

The antidepressant-like effect induced by the sigma(1) (sigma(1)) receptor agonist igmesine involves modulation of intracellular calcium mobilization.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Treatment of psychotic depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

Neuropsychological deficits in psychotic versus nonpsychotic unipolar depression.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900022641

7 January 2021

10.1017/S1092852900022641

Identifiers

DOI

0 references

1 reference